- Home
- EBMT vs CRDF Comparison
EBMT vs CRDF Comparison
Compare EBMT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBMT
- CRDF
- Stock Information
- Founded
- EBMT 1922
- CRDF 1999
- Country
- EBMT United States
- CRDF United States
- Employees
- EBMT N/A
- CRDF N/A
- Industry
- EBMT Major Banks
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EBMT Finance
- CRDF Health Care
- Exchange
- EBMT Nasdaq
- CRDF Nasdaq
- Market Cap
- EBMT 136.9M
- CRDF 144.4M
- IPO Year
- EBMT N/A
- CRDF N/A
- Fundamental
- Price
- EBMT $17.32
- CRDF $2.19
- Analyst Decision
- EBMT
- CRDF Strong Buy
- Analyst Count
- EBMT 0
- CRDF 5
- Target Price
- EBMT N/A
- CRDF $11.10
- AVG Volume (30 Days)
- EBMT 21.8K
- CRDF 1.2M
- Earning Date
- EBMT 10-28-2025
- CRDF 11-06-2025
- Dividend Yield
- EBMT 3.30%
- CRDF N/A
- EPS Growth
- EBMT 49.06
- CRDF N/A
- EPS
- EBMT 1.61
- CRDF N/A
- Revenue
- EBMT $84,696,000.00
- CRDF $545,000.00
- Revenue This Year
- EBMT N/A
- CRDF N/A
- Revenue Next Year
- EBMT $5.20
- CRDF N/A
- P/E Ratio
- EBMT $10.91
- CRDF N/A
- Revenue Growth
- EBMT 5.13
- CRDF N/A
- 52 Week Low
- EBMT $14.35
- CRDF $1.90
- 52 Week High
- EBMT $18.49
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- EBMT 56.12
- CRDF 40.00
- Support Level
- EBMT $17.19
- CRDF $1.90
- Resistance Level
- EBMT $17.99
- CRDF $2.27
- Average True Range (ATR)
- EBMT 0.29
- CRDF 0.12
- MACD
- EBMT 0.02
- CRDF 0.05
- Stochastic Oscillator
- EBMT 48.06
- CRDF 59.18
About EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.